Cafeity Get the app

Medication record

Orforglipron tracker

Orforglipron is a daily GLP-1 tablet, and a different kind of molecule from the rest of the class. For tracking, what matters is the rhythm: one tablet a day, a half-life of a day and a half, and a much flatter week than a weekly injection. Cafeity records it the same way as any other medicine — a dose, a date, an amount — and draws that rhythm from your own log.

By the Cafeity teamUpdated 4 min read

The short answer

Orforglipron is a once-daily GLP-1 receptor agonist tablet for weight management, approved in the US in 2026. Its label gives an elimination half-life of about 29 to 49 hours, a peak 4 to 8 hours after each tablet, and says it can be taken with or without food.1 Cafeity records each tablet, your meals, symptoms and weight on one timeline, and models the level across the day from the published half-life. It never suggests, calculates or adjusts a dose.

Chart of the modelled orforglipron level across 14 daily tablets, rising over the first week to a gently repeating daily pattern about three times the height of a single dose.
The modelled level across 14 daily tablets, from orforglipron's published half-life (about 39 hours, the middle of the 29–49 hour range). Relative to a single dose; a model of the schedule, not a measurement.

At a glance

Figures from the orforglipron US prescribing information; the steady-state figure is arithmetic from the half-life.
Value
FormOnce-daily tablet, swallowed whole, with or without food
Published half-lifeAbout 29 to 49 hours
Time to peak4 to 8 hours after a tablet
SettlesWithin about a week of daily tablets (five half-lives at the mid-range figure)
Used in Cafeity forThe decay constant behind the modelled level, and nothing else

Source: orforglipron prescribing information.1 Nothing on this page is dosing information.

What orforglipron is, in one paragraph

Orforglipron is a GLP-1 receptor agonist taken by mouth once a day. The other medicines in the class are peptides — semaglutide's molecular weight is about 4,100 — whereas orforglipron is a small molecule of about 900.12 It is also taken differently: its label allows it with or without food, whereas semaglutide tablets must be taken on an empty stomach. For everything that belongs on a label — who it is for, who should not take it, interactions, what to watch for — the prescribing information and your prescriber are the right sources.

What a daily tablet changes about tracking

With a weekly injection, the useful question is often "which day of the week was it?". With a daily tablet the level is much flatter, so day-of-week patterns are less likely and other things matter more: the time you took it, whether a tablet was missed, and — for the first weeks and after each change — the fact that the level is still building.

Two label facts are worth having in the record. Oral contraceptives may be less effective: the label advises switching to a non-oral method or adding a barrier method for 30 days after starting and for 30 days after each dose increase.1 And orforglipron interacts with some other medicines through a liver enzyme, so your prescriber and pharmacist need your full medicine list.1

Side effects in the trials

Most common reactions in the two 72-week weight-management trials, from the prescribing information. Placebo alongside for comparison.
ReactionPlacebo5.5 mg9 mg17.2 mg
Nausea10%26%34%35%
Constipation9%20%27%24%
Diarrhoea11%21%23%25%
Vomiting4%13%21%24%
Indigestion4%12%16%13%

The label says nausea, vomiting and diarrhoea were more common during the dose-escalation period and decreased over time.1 See GLP-1 side effects for the full picture.

What the record holds

  • Each tablet — date, time and the amount you were prescribed.
  • Meals, by photo, search or barcode, with protein, fibre and water.
  • Symptoms, including nausea, appetite and food noise, with your own severity rating.
  • Weight as a smoothed trend, not a daily verdict.

Where your data lives

On your device and in your own account, under per-record permissions. Health data is never stored in iCloud, never sold, never used for advertising, and never used as training data. You can export everything in one file, and you can delete the record entirely. The Visit Summary builds a one-page PDF only when you ask it to, and nothing leaves the phone until you share it yourself.

What Cafeity will never do

  • Recommend, calculate or adjust a dose, or tell you when to take one.
  • Interpret a symptom, name a condition, or suggest what is causing something.
  • Predict how much weight you will lose, or when.
  • Set a calorie target below 1,200 kcal, or a weight goal below a BMI of 18.5.

Cafeity is a general wellness product. It does not diagnose, treat, cure, mitigate or prevent any disease or condition. Questions about your treatment belong with a licensed healthcare professional.

Keeping a record of it

Screens from Cafeity on iPhone.

Cafeity Today screen: day 1 of 7 since the last dose with the estimated level at 97% of peak, fibre 21 of 25 g, protein 110 of 100 g, steps, water 850 ml of 2.4 L, the next logged dose and the weight trend.
The day: protein, fibre, water and the next dose you set.
Cafeity medication-level chart over seven days, labelled "Estimate based on published half-life. Not a measurement", with the last dose, the injection site (stomach, upper left), the next scheduled dose and a side-effect check-in.
The modelled level, labelled as an estimate.

Download Cafeity on the App Store

Common questions

Does Cafeity tell me when to take orforglipron?
No. It records what you take and can remind you of a time you set yourself. It never suggests a time, a dose or a change.
Can I take orforglipron with food?
The label says it can be taken with or without food.1 Follow your prescriber's instructions.
How long does orforglipron stay in the body?
Its half-life is about 29 to 49 hours.1 By the five-half-life rule of thumb, most of it is cleared within about 6 to 10 days of the last tablet.

Sources

  1. Orforglipron tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 13 August 2026
  2. Semaglutide injection and tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 30 June 2026

Written by the Cafeity team from the sources listed here. Figures from prescribing information are quoted as the label states them; trial results are averages from those trials, not predictions for any one person. This page has not yet been reviewed by a clinician — see the editorial policy for how pages are researched and corrected.